No Data
No Data
NeueHealth to Host Second Quarter 2024 Earnings Conference Call on August 7, 2024
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Express News | Neuehealth Secures up to $150 Million in New Term Loan Facility With Hercules Capital
Express News | Neuehealth Receives NYSE Non-Compliance Letter Regarding Market Capitalization Requirements
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), BridgeBio Pharma (BBIO) and Biohaven Ltd. (BHVN)
RBC Capital Sticks to Their Hold Rating for NeueHealth Inc (NEUE)
No Data